Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Research Briefs: HeartWare Adds Patients To ENDURANCE; GlySure ICU Glucose Trial; Biotronik Home Monitoring

This article was originally published in The Gray Sheet

Executive Summary

FDA has approved HeartWare’s plan to add more patients to the ENDURANCE trial of its HVAD ventricular assist device as a destination therapy for patients with end-stage heart failure. Results of a pilot trial of GlySure’s continuous glucose monitoring system were presented at a conference in South Africa. More research.

You may also be interested in...



LVAD Makers Report Little Market Impact From Recent Medicare NCD

CMS’s latest national coverage decision for ventricular assist devices has made it more difficult for non-transplant open-heart surgery facilities to implant ventricular assist devices, but the net business impact of the policy overall has been minimal, according to Thoratec and HeartWare.

Proposed NCD May Give Thoratec An Edge Over HeartWare

Tight Glycemic Control: Critical Care’s Balancing Act

Over a decade ago, the New England Journal of Medicine published a study identifying tight glycemic control in the intensive care unit as a critical step to improving patient outcomes. Today, a small pack of companies is trying to finally deliver on the promise.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT032378

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel